Recombinant Human Fibroblast Growth Factor-acidic

Formulation: Lyophilized from 10mM PBS (1mM Na2HPO4, 9mM NaH2PO4, 150mM NaCl, pH6.0)

Mol. Wt.: 16.0kDa

Theory pI: 7.73

Resources: Escherichia coli (E. coli)

Purity: ≥95% by SDS-PAGE analysis

A280nm(1 mg/mL): 1.09

Storage Condition: -20 ℃

Storage Duration: 3 years

Biological Activity: The EC50, calculated by the dose-dependant proliferation of mouse BALB/c 3T3 cells is less than 0.5 ng/ml, corresponding to a specific activity of ≥2×106 units/mg protein.

Description:

Fibroblast Growth Factor-acidic (aFGF), also known as FGF1, is a member of the fibroblast growth factor (FGF) family. The aFGF plays a role in repairing tissue damage, and have nutritional and mitogenic effects on various cells derived from mesoderm and neuroectoderm, including BALB/c 3T3, Fibroblasts, capillary and endocardial cells, myoblasts, vascular smooth muscle cells, mesothelial cells, glial and astrocytes, adrenal cortex cells, etc, having a wide range of biological effects and potential clinical application value.

The aFGF molecule contains a heparin binding region. The combination of aFGF and heparin can increase the activity of some cells, and a certain amount of heparin can increase the stability of aFGF which can protect aFGF from being heated, extreme pH denaturation and protease hydrolysis.

Recombinant human acidic fibroblast growth factor (rh-aFGF), expressed in E. coli , is a non-glycosylated single-chain protein, containing 141 amino acids and having a molecular weight of 16.0 kDa.

For research use only! 

Packing: In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.

Application: This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

Stability & storage conditions:

Use a manual defrost freezer. No activity loss was observed after storage at:

4-8°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

Frontiers progress:

· Proteoglycan/glycosaminoglycan and collagen content in the arterial wall of patients with end-stage renal disease - new indicators for vascular disease

Author: Batko Krzysztof K, Krzanowski Marcin M, Gajda Mariusz M, Dumnicka Paulina P, Pietrzycka Agata A, Fedak Danuta D, Woziwodzka Karolina K, Gołasa Paulina P, Kuźniewski Marek M

Journal: 2019-10-15  DOI : 10.1002/smll.201802403 

Abstract: + Cardiovascular (CV) comorbidity is high in chronic kidney disease, particularly in end-stage renal disease (ESRD).

· Rifampicin, Not Vitamin E, Suppresses Parenteral Nutrition Associated Liver Disease Development through Pregnane X Receptor Pathway in Piglets

Author: Guthrie Gregory G, Stoll Barbara B, Chacko Shaji S, Lauridsen Charlotte C, Plat Jogchum J

Journal: Am. J. Physiol. Gastrointest. Liver Physiol. 2019-10-11  DOI : 10.1002/smll.201802403 

Abstract: + Infants receiving long-term parenteral nutrition (PN) develop PN associated liver disease (PNALD).

· Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice

Author: Liu Yunhuan Y, Chen Kefei K, Li Fengyuan F, Gu Zelin Z, Liu Qi Q, He Liqing L, Shao Tuo T, Song Qing Q, Zhu Fenxia F

Journal: Hepatology 2019-09-30  DOI : 10.1002/smll.201802403 

Abstract: + Cholestatic liver disease is characterized by gut dysbiosis and excessive toxic hepatic bile acids (BAs).